Rhona Jack

Dr. Rhona Jack


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
FSFrederick G. Strathmann
Frederick G. Strathmann
KSKaterina Sadilkova
Katerina Sadilkova
TLThomas J. Laha
Thomas J. Laha
SLSusan E. LeSourd
Susan E. LeSourd
JBJoshua A. Bornhorst
Joshua A. Bornhorst
RJRhona Jack
Rhona Jack

21 November 2014 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
JDJane Dickerson
Jane Dickerson
MSMarian Sinkey
Marian Sinkey
KJKathleen Jacot
Kathleen Jacot
JSJennifer Stack
Jennifer Stack
KSKaterina Sadilkova
Katerina Sadilkova
RJRhona Jack
Rhona Jack

14 March 2019 in JIMD Reports
Verified
Journal Article
Open access
RJRhona Jack
Rhona Jack
CSC. Ronald Scott
C. Ronald Scott
The drug nitisinone (NTBC; Orfadin, Vienna, Austria) has been used for the treatment of hereditary tyrosinemia type‐1 since 1991. Nitisinone effectively blocks the metabolism of tyrosine to prevent the formation of the toxic compound succinylacetone (and precursor fumarylacetoacetate) in affected children. Monitoring of plasma drug levels and urine succinylacetone can be used to assess compliance and adequate dose of drug. We present retrospective data from patient monitoring for over 10 years that provide validation of a target therapeutic range for nitisinone of 40 to 60 μmol/L. The target nitisinone range is justified as valid based on reduction of succinylacetone excretion. There was no statistical significance in succinylacetone excretion in mmol/mol creatinine above a level of 40 μmol/L plasma NTBC (P > 0.05).

1 May 2017 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Closed access
PDF file
JDJane Dickerson
Jane Dickerson
TPTracey G. Polsky
Tracey G. Polsky
DGDina N. Greene
Dina N. Greene
PSParisa Salehi
Parisa Salehi
ARAlissa J. Roberts
Alissa J. Roberts
RJRhona Jack
Rhona Jack

1 October 2018 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
RJRhona Jack
Rhona Jack
This case is an excellent illustration of our opportunity as laboratory professionals to ensure accuracy of laboratory results and provide insight into potential causes of method interference. Understanding the strengths and limitations of the method used is critical to the goal of accuracy, as is having staff available who have the clinical knowledge to determine what makes sense clinically. The presence of allo-ile is a cause for concern. Although …